Cannara Biotech (STU:8CB0) Cash And Cash Equivalents : €3.39 Mil (As of Feb. 2025)

View and export this data going back to 2019. Start your Free Trial

What is Cannara Biotech Cash And Cash Equivalents?

Cannara Biotech's quarterly cash and cash equivalents increased from Aug. 2024 (€4.40 Mil) to Nov. 2024 (€6.92 Mil) but then stayed the same from Nov. 2024 (€6.92 Mil) to Feb. 2025 (€3.39 Mil).

Cannara Biotech's annual cash and cash equivalents declined from Aug. 2022 (€9.26 Mil) to Aug. 2023 (€2.91 Mil) but then increased from Aug. 2023 (€2.91 Mil) to Aug. 2024 (€4.40 Mil).

Cannara Biotech Cash And Cash Equivalents Historical Data

The historical data trend for Cannara Biotech's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cannara Biotech Cash And Cash Equivalents Chart

Cannara Biotech Annual Data

Trend

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Aug24

Cash And Cash Equivalents

Get a 7-Day Free Trial

4.96

5.51

9.26

2.91

4.40

Cannara Biotech Quarterly Data
	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24	Feb25
Cash And Cash Equivalents	Get a 7-Day Free Trial															2.15	3.70	4.40	6.92	3.39

Cannara Biotech Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Cannara Biotech (STU:8CB0) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Cannara Biotech Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Cannara Biotech's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Cannara Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannara Biotech Inc (STU:8CB0) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

LOVFF:USA 8CB0:Germany LOVE:Canada

Address

1055 West Georgia Street, Suite 2050, Vancouver, BC, CAN, V6E 3P3

Website

http://www.cannara.ca

Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .

Cannara Biotech Headlines

No Headlines